Hepatitis C Trial Design To Be Discussed By FDA’s Antiviral Drugs Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
The Oct. 19-20 meeting will focus on control arms, endpoints and long-term follow-up.
You may also be interested in...
Schering-Plough Takes The Long Road To Early Stage Hep C R&D
The firm is conducting a 24-week, Phase II study in non-responders to pegylated interferon and ribavirin.
Schering-Plough Takes The Long Road To Early Stage Hep C R&D
The firm is conducting a 24-week, Phase II study in non-responders to pegylated interferon and ribavirin.
Novartis Bolsters Hep C Pipeline With Human Genome Sciences Collaboration
Agreement gives Novartis rights to Albuferon, a Phase III interferon. In a separate agreement with Cytopia, Novartis will develop JAK3 inhibitors for autoimmune diseases and transplant rejection.